EUVIMEDEUVIMED entdecken
Open Access

Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes

Pradeep Annamalai Subramani iD, Phornpimon Tipthara, Surendra Kumar Kolli iD, Justin Nicholas, Samantha J Barnes, Madison M Ogbondah, Kevin C Kobylinski iD, Joel Tarning, John H Adams iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01272-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Pradeep Annamalai Subramani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health and Interdisciplinary Research, College of Public Health, University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Ivermectin, Hepatocytes, Plasmodium falciparum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ivermectin, a broad-spectrum anti-parasitic drug, has been proposed as a novel vector control tool to reduce malaria transmission by mass drug administration. Ivermectin and some metabolites have mosquito-lethal effect, reducing Anopheles mosquito survival. Ivermectin inhibits liver stage development in a rodent malaria model, but no inhibition was observed in a primate malaria model or in a human malaria challenge trial. In the liver, cytochrome P450 3A4 and 3A5 enzymes metabolize ivermectin, which may impact drug efficacy. Thus, understanding ivermectin metabolism and assessing this impact on Plasmodium liver stage development is critical. Using primary human hepatocytes (PHHs), we characterized ivermectin metabolism and evaluated the efficacy of ivermectin and its primary metabolites M1 (3″- O -demethyl ivermectin) and M3 (4-hydroxymethyl ivermectin) against Plasmodium falciparum liver stages. Two different modes of ivermectin exposure were evaluated: prophylactic mode (days 0–3 post-infection) and curative mode (days 3–5 post-infection). We used two different PHH donors and modes to determine the inhibitory concentration (IC 50 ) of ivermectin, M1, M3, and the known anti-malarial drug pyrimethamine, with IC 50 values ranging from 1.391 to 14.44, 9.95–23.71, 4.767–8.384, and 0.9073–5.416 µM, respectively. In our PHH model, ivermectin and metabolites M1 and M3 demonstrated inhibitory activity against P. falciparum liver stages in curative treatment mode (days 3–5) and marginal activity in prophylactic treatment mode (days 0–3). Ivermectin had improved efficacy when co-administered with ketoconazole, a specific inhibitor of cytochrome P450 3A4 enzyme. Further studies should be performed to examine ivermectin liver stage efficacy when co-administered with CYP3A4 inhibitors and anti-malarial drugs to understand the pharmacokinetic and pharmacodynamic drug-drug interactions that enhance efficacy against human malaria parasites in vitro .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvermectinHepatocytesPlasmodium falciparumHumansCytochrome P-450 CYP3AAntimalarialsLiverMalaria, FalciparumAnimalsCells, CulturedAnopheles

Stichwörter der Autor:innen

Plasmodiumcytochrome P450 CYP3A4drug metabolismivermectinliver stage

Substanzen

IvermectinCytochrome P-450 CYP3AAntimalarialsCYP3A4 protein, human

Autor:innen und Institutionen

  • Center for Global Health and Interdisciplinary Research, College of Public Health, University of South Florida, Tampa, Florida, USA.
  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Pradeep Annamalai Subramani, Surendra Kumar Kolli, Kevin C Kobylinski, John H Adams

Förderung

  • NIAID NIH HHS
  • HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID)

Zitieren

APA

Annamalai Subramani, P., Tipthara, P., Kolli, S. K., Nicholas, J., Barnes, S. J., Ogbondah, M. M., Kobylinski, K. C., Tarning, J., & Adams, J. H. (2024). Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01272-23

Vancouver

Annamalai Subramani P, Tipthara P, Kolli SK, Nicholas J, Barnes SJ, Ogbondah MM, et al. Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01272-23

BibTeX
@article{AnnamalaiSubramani2024,
  author = {Annamalai Subramani, Pradeep and Tipthara, Phornpimon and Kolli, Surendra Kumar and Nicholas, Justin and Barnes, Samantha J and Ogbondah, Madison M and Kobylinski, Kevin C and Tarning, Joel and Adams, John H},
  title = {Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01272-23}
}
Kostenlos starten →